Literature DB >> 16949767

Frequency and characteristics of docetaxel-induced radiation recall phenomenon.

Masashi Mizumoto1, Hideyuki Harada, Hirofumi Asakura, Sadamoto Zenda, Hiroshi Fuji, Shigeyuki Murayama, Tetsuo Nishimura.   

Abstract

PURPOSE: The aim of this study was to investigate the frequency and characteristics of a docetaxel-induced radiation recall phenomenon. METHODS AND MATERIALS: Past histories of radiotherapy and radiation recall phenomenon (RRP) were analyzed in 461 patients who were administered docetaxel at our hospital between September 2002 and November 2005.
RESULTS: Of the 461 patients, 171 underwent radiotherapy before starting docetaxel. RRP was noted in 3 patients (1.8%). The 3 cases show that RRP tends to develop in patients treated with lower-energy photon beams of < or =6 MV and in patients with marked acute phase reactions during radiotherapy.
CONCLUSIONS: The incidence of RRP induced by docetaxel was 1.8%, making it a comparatively rare condition. However, docetaxel is increasingly being used for patients with head and neck tumors, and caution regarding development of RRP is warranted after use of docetaxel after high-dose radiotherapy with photon beams of < or =6 MV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949767     DOI: 10.1016/j.ijrobp.2006.05.073

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Gemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinoma.

Authors:  Sagar C Patel; Arnold C Paulino; Danielle Johnston; Lee Wiederhold; Richard Castillo; Rajkumar Venkatramani
Journal:  Pract Radiat Oncol       Date:  2016-06-15

Review 2.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

3.  Docetaxel induces radiation recall myositis: A case report.

Authors:  Ayşegül Üçüncü Kefeli; Beyza Aksu
Journal:  Exp Ther Med       Date:  2022-06-15       Impact factor: 2.751

4.  Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.

Authors:  Vinita Takiar; Eric A Strom; Donald P Baumann; Funda Meric-Bernstam; Ricardo H Alvarez; Ana M Gonzalez-Angulo
Journal:  Oncologist       Date:  2013-02-12

Review 5.  Docetaxel-induced radiation recall dermatitis : A case report and literature review.

Authors:  Iosif Strouthos; Nikolaos Tselis; Nikolaos Zamboglou
Journal:  Strahlenther Onkol       Date:  2016-06-10       Impact factor: 3.621

Review 6.  Radiation recall with anticancer agents.

Authors:  Howard A Burris; Jane Hurtig
Journal:  Oncologist       Date:  2010-11-02

Review 7.  The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.

Authors:  Witold Owczarek; Monika Słowińska; Aleksandra Lesiak; Magdalena Ciążyńska; Aldona Maciąg; Elwira Paluchowska; Luiza Marek-Józefowicz; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

8.  Sociodemographic, clinical profile, and treatment characteristics of oncology patients developing radiation recall phenomenon: Two tertiary care center's experience of an eternal unpredictable phenomenon of cancer treatment.

Authors:  Abhishek Purkayastha; Neelam Sharma; Sachin Taneja; Virender Suhag; Nishant Lohia
Journal:  Tzu Chi Med J       Date:  2021-12-10

9.  Radiation recall dermatitis: case report and review of the literature.

Authors:  A E Hird; J Wilson; S Symons; E Sinclair; M Davis; E Chow
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

10.  Docetaxel-induced radiation recall dermatitis with atypical features: A case report.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.